	US 11,931,367 B2
	Oral (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate therapy
Kilyoung Kim, West Jordan, UT (US); Mahesh V. Patel, Salt Lake City, UT (US); and Nachiappan Chidambaram, Sandy, UT (US)
Filed by Lipocine Inc., Salt Lake City, UT (US)
Filed on Sep. 30, 2021, as Appl. No. 17/490,866.
Prior Publication US 2023/0113311 A1, Apr. 13, 2023
Int. Cl. A61K 31/568 (2006.01); A61K 9/00 (2006.01); G16H 20/10 (2018.01)

CPC A61K 31/568 (2013.01) [A61K 9/0053 (2013.01); G16H 20/10 (2018.01)]

96 Claims

1. A method of administering a treatment regimen for a condition associated with hypogonadism comprising:

administering to a subject an initial dosage comprising at least one dose of a pharmaceutical composition comprising (17β)-3-oxoandrost-4-en-17-yl tridecanoate,

obtaining a steady state androst-4-en-17β-ol-3-one serum concentration level of said subject, and

administering to said subject at least one maintenance dosage comprising at least one dose of said pharmaceutical composition comprising (17β)-3-oxoandrost-4-en-17-yl tridecanoate.